Hofseth BioCare ASA: Key OmeGo(TM) patent notice of allowance in the US and new study on ProGo(TM)

Hofseth BioCare ASA («HBC») is pleased to announce that the US patent office has issued a Notice of Allowance on one of HBC's key licensed-in salmon oil patent applications - "Method of lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosis".
 
The grant of this patent will allow HBC to bolster its marketing for improved heart health with a unique and proprietary mechanism of action now with patent protection in the largest nutraceutical market in the world.
 
HBC has also just completed a new study to evaluate the efficacy of Endurance tablets of ProGo(TM) to increase vitality, energy and general wellbeing in normal patients. The study was done with 4 grams per day of ProGo(TM) Endurance tablets for 4 weeks.
 
The study showed a significant increase in energy, vitality and improvement in general wellbeing after the 4 week trial. This trial shows that even small doses of ProGo(TM) will stimulate energy and vitality in normal individuals.
 
For more information, please contact:
Jon Olav Ødegård, CEO Hofseth BioCare ASA
Mobile: +47 936 32 966
Email: joo@hofsethbiocare.no
 
About Hofseth BioCare ASA:
HBC is a Norwegian biotech company that offers high-value ingredients and
finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. HBC's objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.
 
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.